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Simple Summary: Pancreatic acinar cell carcinoma accounts for less than 1% of primary pancreatic
neoplasms. Because of its rarity, its characteristics and clinical outcomes remain unclear. Treatment
strategies for pancreatic acinar cell carcinoma have relied on those of pancreatic ductal adenocar-
cinoma. In previous studies, it has been difficult to identify its characteristics due to the lack of
cohort numbers in single institutional studies with detailed data and the lack of detailed data in large
cohort multi-institutional studies. This retrospective multicenter cohort used a database founded in
2015 by the Korean Association of Hepato-Biliary Pancreatic Surgery. This database has collected
nationwide patient data with details. In the present study, we aimed to better understand clinical
outcomes of resected pancreatic acinar cell carcinoma and to lay the groundwork for establishing
proper treatment strategies.
Abstract: Given the rare incidence of pancreatic acinar cell carcinoma (PACC), its post-resection
clinical outcomes remain unclear. Treatment strategies for PACC have relied on those of pancreatic
ductal adenocarcinoma (PDAC). The present study retrospectively investigated clinicopathologic
characteristics of resected PACC registered in the Korea Tumor Registry System Biliary Pancreas
database. Among 59 patients with a mean age of 59.2 years and a male predominance (83.1%), 43, 5,
7, and 4 had pure PACC, ductal differentiations, mixed neuroendocrine carcinomas, and intraductal
and papillary variants, respectively. The mean tumor size was 4.6 cm, consisting of eight at T1, 26 at
T2, and 25 at T3 stages. Metastasis to regional lymph node was identified in 15 (25.4%) patients.
Thirty-one (52.5%) patients received adjuvant therapy. Five-year survival rate was 57.4%. The median
survival was 78.8 months. In survival comparison according to the stage with AJCC system, N stage
(lymph node metastasis), but not T stage, showed significant differences (p = 0.027). Resected PACC
appeared to have clinical outcomes distinct from those of PDAC in this nationwide study. Therefore,
large-scale multinational studies are needed to overcome the rarity of PACC and to establish an
appropriate treatment strategies and staging system.
Keywords: pancreatic acinar cell carcinoma; acinar cell carcinoma; pancreatic cancer
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1. Introduction
The pancreas is an organ with exocrine and endocrine functions. The cells that
occupy most of the exocrine cells are acinar cells that can secrete pancreatic enzymes [1].
Nevertheless, most malignant tumors originating from the exocrine pancreas are pancreatic
ductal adenocarcinoma (PDAC), with pancreatic acinar cell carcinoma (PACC) accounting
for less than 1% of primary pancreatic neoplasms [2–4]. Because of the rarity of PACC,
it is difficult to know the exact characteristics of this disease and clinical course, as most
studies reported to date only have limited numbers with data from single-center studies or
multicenter studies [5–10].
It has been revealed that PACC is larger than PDAC at the time of diagnosis, with
much better prognosis than PDAC [7–9,11–13]. However, its clinical outcome after surgical
resection remains unknown. Studies on the role of adjuvant therapy and appropriate
regimen for PACC are also insufficient. In American Joint Committee on Cancer (AJCC)
staging, the staging of PACC is not differentiated from that of PDAC, but it is classified as
an exocrine pancreatic cancer [14]. Although adjuvant therapy would offer the potential
for reducing the risk of recurrence, a clear benefit of using adjuvant therapy has not been
shown yet. Previous studies on adjuvant strategies for PACC have shown mixed results
regarding their efficacies [6,8,15,16], which have mostly relied on studies of PDAC.
PACC is clearly a disease originating from cells different from PDAC, which requires
independent research. Therefore, the purpose of the present study was to better understand
the clinical outcome of resected PACC using the Korea Tumor Registry System Biliary
Pancreas (KOTUS-BP), a Korean nationwide database, and to lay the groundwork for
establishing proper treatment strategies.
2. Materials and Methods
2.1. Patients Database
This retrospective multicenter cohort study used a database founded in 2015 by the
Korean Association of Hepato-Biliary Pancreatic Surgery (KAHBPS). This database, called
KOTUS-BP, collected nationwide patient data retrospectively from institutions of KAHBPS
members. There were 59 patients with biopsy-proven PACC resected with curative in-
tention from the following seven institutions between January 2003 and December 2018:
Severance Hospital, Ewha Womans University Hospital, Seoul National University Hospi-
tal, Seoul National University Bundang Hospital, Asan Medical Center, National Cancer
Center, and Samsung Medical Center. Their clinicopathological, surgical, and postoperative
data were reviewed, and their survival data were updated by each institution. This study
was approved by our Institutional Review Board (IRB) (approval number: 2021-09-222).
The requirement for written informed consent from participants was waived by our IRB
due to the study’s retrospective nature.
Tumor, node, and metastasis (TNM) staging were classified according to the AJCC
Cancer Staging Manual, 8th edition [14]. Resection margin status was categorized as R0
or R1. If the closest safe resection margin was less than 1 mm, it was categorized as an R1
margin [17,18]. Overall survival was measured as the period between surgery and death
or the last visit to the outpatient center.
2.2. Statistical Analysis
All statistical analyses were performed using IBM SPSS 24 (SPSS Inc., Chicago, IL,
USA). Probability (p) values of 0.05 or less were considered statistically significant. Actu-
arial survival and comparison of univariable analyses were performed using the Kaplan–
Meier method with the log-rank test. Multivariable analysis was conducted using a Cox
proportional hazard model to identify factors affecting patients’ overall survival.
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3. Results
3.1. Patients’ Characteristics
Patients’ characteristics are summarized in Table 1. Of a total of 59 patients, there was
a male predominance (83.1%). The mean age at diagnosis was 59.2 years. Preoperative CEA
and CA19-9 levels were elevated in two (3.4%) and seven (11.9%) patients, respectively.
The most predominant surgery was pancreaticoduodenectomy/pylorus-preserving pan-
creaticoduodenectomy (PD/PPPD) (n = 30, 50.8%), followed by distal pancreatectomy (DP)
(n = 21, 35.6%). The mean tumor size at surgery was 4.6 cm. Historical variants of PACC
were observed in 16 (27.1%) patients, including ductal differentiation in 5 (8.5%), mixed
acinar-neuroendocrine carcinoma in 7 (11.9%), and intraductal and papillary variants in
4 (6.8%). According to cancer staging of AJCC 8th edition, 8 (13.6%), 26 (44.1%), and
25 (42.4%) patients had T1, T2, and T3 tumors, respectively. Lymph node metastasis was
found in 15 (25.4%), consisting of 11 (18.6%) of N1 and 4 (6.8%) of N2. Complete micro-
scopic resection (R0) was achieved in 55 (93.2%). In terms of adjuvant therapy, 31 (52.5%)
patients underwent chemotherapy (n = 22, 37.3%) or concurrent chemo-radiation therapy
(n = 9, 15.3%).
Table 1. Characteristics of patients (n = 59).
Characteristics n (%) or Mean (±SD) Characteristics n (%) or Mean (±SD)
Age, year 59.2 (±11.6) T stage, AJCC 8th edition -
BMI, kg/m2 23.3 (±3.3) T1 8 (13.6)
Sex - T2 26 (44.1)
Male 49 (83.1) T3 25 (42.4)
Female 10 (16.9) N stage, AJCC 8th edition -
CEA - N0 44 (74.6)
Normal 55 (93.2) N1 11 (18.6)
Elevated 2 (3.4) N2 4 (6.8)
NA 2 (3.4) Staging, AJCC 8th edition -
CA19-9 - Stage IA 8 (13.6)
Normal 47 (79.7) Stage IB 16 (27.1)
Elevated 7 (11.9) Stage IIA 20 (33.9)
NA 5 (8.5) Stage IIB 11 (18.6)
Surgery - Stage III 4 (6.8)
PD/PPPD 30 (50.8) R status -
DP 21 (35.6) R0 55 (93.2)
TP 3 (5.1) R1 4 (6.8)
CP 1 (1.7) Adjuvant therapy -
Enucleation 4 (6.8) No 28 (47.5)
Tumor location - Chemotherapy 22 (37.3)
Head 33 (55.9) Chemo-Radiation therapy 9 (15.3)
Body 3 (5.1) Chemotherapy regimen -
Tail 22 (37.3) No 28 (47.5)
Diffuse 1 (1.7) 5-fluorouracil based 18 (30.5)
Size, cm 4.6 (3.0) Gemcitabine based 13 (22.0)
Pathology - - -
Acinar cell carcinoma 43 (72.9) - -
Ductal differentiation 5 (8.5) - -
Neuroendocrine mixed 7 (11.9) - -
Intraductal and papillary
variant 4 (6.8) - -
SD = standard deviation, BMI = body mass index, NA = not available, PD/PPPD = pancreaticoduodenectomy/pylorus-preserving
pancreaticoduodenectomy, DP = distal pancreatectomy, TP = total pancreatectomy, CP = central pancreatectomy, AJCC = American Joint
Committee on Cancer.
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3.2. Treatment Outcomes and Prognostic Factors
With a median follow-up period of 30.3 months, the median disease-free survival was
30.9 months, and the median overall survival was 78.8 months (Figure 1). Five-year disease-
free survival and overall survival rates were 38.5% and 57.4%, respectively (Figure 1).
Figure 2 shows survival comparisons according to cancer staging of the exocrine pancreatic
tumor of the AJCC 8th edition. While N2 regional lymph node metastasis showed poorer
prognosis than N0 (p = 0.011), N0 and N1 did not reflect survival differences (Figure 2A).
In patients without regional lymph node metastasis (N0), T stage did not show survival
differences between each stage (Figure 2B). The median survival was 77.4 months in
stage IA, not reached in stage IB, 78.8 months in stage IIA, 57.6 months in stage IIB, and
20.2 months in stage III (Figure 2C).
In terms of adjuvant therapy, the kind of therapeutic modality did not show significant
survival differences (Figure 3A). Although gemcitabine (GEM)-based chemotherapy did not
show significant survival difference compared with no therapy (p = 0.518) or compared with
5-fluorouracil (5-FU)-based chemotherapy (p = 0.196), 5-fluorouracil-based chemotherapy
showed poorer survival than no adjuvant therapy (p = 0.035, Figure 3B).
Multivariable analysis using a Cox proportional hazard model (Table 2) revealed that
patients’ overall survival was poor if they had elevated CA19-9 level (hazard ratio (HR):
24,078), N2 stage (HR: 13,882), and 5-fluorouracil-based chemotherapy (HR: 5733). On
the other hand, an intraductal and papillary variant was associated with better survival
(HR: 0.018).
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ing [14]. (A) When the analysis considered N stage (n = 59), there was a significant difference be-
tween N0 and N2 (p = 0.011), although there was no significant difference in comparison of N0 vs. 
N1 (p = 0.246) or N1 vs. N2 (p = 0.219). The median survival was 96.3 months in N0, 57.6 months in 
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In terms of adjuvant therapy, the kind of therapeutic modality did not show signifi-
cant survival differences (Figure 3A). Although gemcitabine (GEM)-based chemotherapy 
Figure 2. Kaplan–Meier survival curves according to the American Joint Committee on Cancer staging [14]. (A) When
the analysis considered N stage (n = 59), there was a significant difference between N0 and N2 (p = 0.011), although there
was no significant difference in comparison of N0 vs. N1 (p = 0.246) or N1 vs. N2 (p = 0.219). The median survival was
96.3 months in N0, 57.6 months in N1, and 20.2 months in N2. (B) When the analysis considered T stage in N0 patients
(n = 44), there was no significant difference between T stages (p = 0.604 for T1 vs. T2, p = 0.263 for T2 vs. T3, and p = 0.729 for
T1 vs. T3). The median survival was 77.5 months in T1, not reached in T2, and 78.8 months in T3. (C) The median survival
was 77.4 months in stage IA, not reached in stage IB, 78.8 months in stage IIA, 57.6 months in stage IIB, and 20.2 months in
stage III. Stage III showed significant differences with other stages (p = 0.21 for IA vs. III and p = 0.39 for IIA vs. III).
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(Months) p p Hazard Ratio 95% CI
Elevated CA 19-9 52.5 0.045 0.01 24.078 2137–271,319
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variant Not reached 0.023 0.014 0.018 0.001–0.445
N2 stage 20.2 0.036 0.027 13.882 1339–143,931
5-fluorouracil-based 53.0 0.042 0.048 5.733 1015–32,379
CI = confidence interval.
4. Discussion
The present study revealed the characteristics and postoperative outcomes of resected
PACC using a multi-institutional database of Korea. Compared with PDAC, PACC was
detected at a younger age. In addition, tumor markers including CEA and CA19-9 did
not seem to be sensitive markers in terms of clinical features of PACC. In terms of patho-
logical features, PACC had a relatively larger size and lower rate of regional lymph node
metastases than PDAC. TNM staging of exocrine pancreatic tumor of AJCC could not
discriminate survival difference in PACC. In addition, PACC had better survival than
PDAC, although current adjuvant therapy did not show a clear survival-improving effect.
In terms of tumor markers, elevated level of serum CA19-9 has been accepted as a
sensitive marker for diagnosis of pancreatic cancer, with a pooled sensitivity of 75.4% in a
previous meta-analysis [19]. Although CA19-9 can be elevated in non alignant diseases
and other gastrointestinal tumors, it is elevated in approximately 65% of patients with
pancreatic cancer. It has been the most widely accepted marker and prognostic factor to
date for evaluating the performance of a treatment as well as for the diagnosis of initial
or recurrent pancreatic cancer [20–27]. However, it is limited to studies on PDAC. In the
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present study, CA19-9 was elevated in only 11.9% of patients with PACC, similar to results
of a previous study [9]. Although its elevation was associated with poorer survival (HR:
24,078, 95% CI: 2137–271,319), PACCs with normal CA19-9 levels accounted for a much
larger proportion. Its prognostic value should be re-assessed in a larger cohort.
In most previous studies on PDAC, the mean tumor size at surgery is approximately
3 cm, and regional lymph node metastases are found for more than half of resected
PDAC [25]. These two factors are always considered as prognosticators. Therefore, TNM
cancer staging of exocrine pancreatic tumor in AJCC 8th edition was established for tumor
size and number of regional lymph node metastasis. The present study showed that
tumor size (T stage) did not reflect survival differences in resected PACC. Although lymph
node metastasis (N stage) was significantly associated with survival, the rate of metastatic
lymph node was low. It seemed difficult to adequately reflect the survival difference of
resected PACC.
In terms of adjuvant therapy for resected pancreatic cancer, 5-FU- or GEM-based
chemotherapy has been the mainstream regimen [28–32]. Although there has been no
innovative medicine yet, various therapeutic strategies for adjuvant therapy have been
recommended for patients with “pancreatic ductal adenocarcinoma”, showing effective
benefit for survival. Although similar strategies have been applied to PACC in many insti-
tutes, the efficacy of adjuvant therapy has shown mixed results in previous studies [33,34].
Prospective randomized trials are still lacking. In the present study, 52.7% of all cohorts
received adjuvant therapy including 5-FU- or GEM-based chemotherapy. Survival compari-
son showed that neither the therapeutic regimen nor the adjuvant therapy itself contributed
to survival improvement. Rather, multivariable analysis showed poor survival in patients
receiving 5-FU-based chemotherapy, which was thought to be due to the small number of
study cohorts.
Although the present study was conducted using a nationwide multi-institutional
database, there are limitations related to its retrospective design and the rarity of the disease.
Patient cohorts of this study were inconsistent, including inaccurate diagnosis preopera-
tively and inconsistent postoperative treatment between institutions due to the lack of a
unified therapeutic strategy. For example, since the adjuvant therapeutic strategies includ-
ing chemotherapeutic regimen or radiotherapy were applied quite differently depending
on the institution or physician, the exact chemotherapeutic regimen or radiotherapeutic
dose could not be clearly presented in this study. Because of such inconsistency, there might
be a limitation in understanding the natural history of resected PACC or the exact role
of adjuvant therapy. In addition, despite a nationwide database being used to overcome
the rarity, it still seemed difficult to completely overcome the numerical limitations of this
rare disease. However, the present study was a study using the database of KAHBPS
(KOTUS-BP), which contained detailed data from multi-institutions across the country to
overcome the numerical limitations of a single institution [9,15] and the lack of detailed
data of large cohorts [11,13] shown in previous studies.
5. Conclusions
In conclusion, although it was impossible to determine definite characteristics of
PACC from this nationwide study, it confirmed that PACC and PDAC were clearly different
diseases. The staging system designed based on the study of PDAC does not reflect the
prognosis of PACC, and it is uncertain whether adjuvant therapeutic strategies targeting
PDAC improve the prognosis of PACC. Further research is needed to establish through
international collaboration proper treatment strategies for PACC.
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